Cerestat CNS 1102 data

CNSI (Cambridge, Mass.) reported on an open-label Phase 1/II trial in 29 patients who had suffered severe head iniury in the previous 72 hours, showing no adverse effects and demonstrating improvement in two surrogate markers of functional outcome.

As detailed at the American Neurological Association meeting in San Francisco, improvement in cerebral perfusion pressure and in intracranial pressure (ICP) occurred progressively with infusions of each of the five doses tested. Infusion time was 4.25 hours. ...